Tapentadol

Acute Pain Relief

The immediate-release form of tapentadol is used to manage moderate to severe acute pain. This typically includes short-term pain resulting from an injury or a surgical procedure.

Chronic Pain Management

The extended-release form of tapentadol is used for severe pain that is expected to last for a long period. It is intended for patients who need continuous, daily, around-the-clock treatment because other pain management options, such as non-opioid medications or immediate-release opioids, are not effective or cannot be tolerated.

Diabetic Nerve Pain

Extended-release tapentadol is also used to treat a specific type of chronic pain called diabetic peripheral neuropathy. This is severe nerve pain that occurs in the hands or feet of people with diabetes.

Dual Mechanism of Action

Tapentadol belongs to a class of drugs known as opioid analgesics. It is unique because it treats pain through two different pathways in the central nervous system:

• Opioid Receptor Activation: The drug binds to specific sites called mu-opioid receptors in the brain and spinal cord. By attaching to these receptors, it alters the way the body feels and reacts to pain signals.
• Norepinephrine Reuptake Inhibition: Tapentadol also increases the levels of norepinephrine, a natural chemical messenger, in the spaces between nerve cells. It does this by preventing the chemical from being reabsorbed too quickly. Higher levels of norepinephrine help block pain messages from traveling up the spinal cord to the brain.

By combining these two methods, tapentadol provides relief for moderate to severe pain that may not be adequately managed by other types of treatment. It is designed to act directly on the central nervous system to decrease the sensation of pain.

Common Side Effects

Tapentadol may cause several common side effects as the body adjusts to the medication. These typically include:

• Nausea and vomiting
• Constipation
• Dizziness or drowsiness
• Headache
• Dry mouth
• Tiredness
• Itching
• Increased sweating

Serious Side Effects

Some side effects can be severe. Contact a healthcare provider immediately or seek emergency care if you experience:

• Slow or shallow breathing: Difficulty breathing, shortness of breath, or periods where breathing stops.
• Serotonin syndrome: A potentially life-threatening reaction characterized by agitation, hallucinations, rapid heartbeat, muscle twitching, shivering, or severe nausea and diarrhea.
• Severe allergic reactions: Swelling of the face, throat, or tongue, hives, or a severe skin rash.
• Seizures: Uncontrolled muscle movements or convulsions.
• Adrenal insufficiency: Symptoms such as extreme tiredness, loss of appetite, or muscle weakness.
• Low blood pressure: Feeling lightheaded or fainting, especially when standing up quickly.
• Extreme sleepiness: Feeling like you cannot stay awake or may pass out.

Boxed Warnings

• Addiction, Abuse, and Misuse: Tapentadol exposes users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death.
• Respiratory Depression: Serious, life-threatening, or fatal breathing problems may occur. Monitoring is especially important during treatment initiation or dose increases.
• Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can result in a fatal overdose.
• Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in withdrawal symptoms in the newborn, which may be life-threatening if not recognized and treated.
• Interactions with Benzodiazepines and CNS Depressants: Using tapentadol with benzodiazepines, alcohol, or other central nervous system depressants may result in profound sedation, respiratory depression, coma, and death.

Contraindications

Tapentadol should not be used in patients with:

• Significant respiratory depression or acute/severe bronchial asthma in unmonitored settings.
• Known or suspected gastrointestinal obstruction, including paralytic ileus.
• Hypersensitivity to tapentadol or its components.
• Current or recent use (within 14 days) of monoamine oxidase inhibitors (MAOIs) due to the risk of cardiovascular events.

Other Precautions

• Serotonin Syndrome: A potentially life-threatening condition may occur, particularly when tapentadol is used with other drugs that affect the serotonin system.
• Seizures: Tapentadol may increase the risk of seizures, especially in patients with a history of seizure disorders or those taking other medications that lower the seizure threshold.
• Adrenal Insufficiency: Cases of adrenal insufficiency have been reported with opioid use, often after more than one month of use.
• Severe Hypotension: Tapentadol may cause a significant drop in blood pressure, particularly when standing up (orthostatic hypotension).
• Increased Intracranial Pressure: Use with caution in patients with head injuries or brain tumors, as the drug may further increase pressure inside the skull or mask clinical signs.

Pregnancy

Prolonged use of tapentadol during pregnancy can cause neonatal opioid withdrawal syndrome. This condition occurs because the baby may become dependent on the medication while in the womb and experience withdrawal after birth. Symptoms in the newborn can include high-pitched crying, irritability, tremors, vomiting, and difficulty gaining weight. If not recognized and treated, this condition can be life-threatening.

Using tapentadol close to the time of delivery may also cause the newborn to have slowed or shallow breathing. It is important to discuss the risks and benefits of this medication with a healthcare provider if pregnancy is possible or planned.

Breastfeeding

Tapentadol is known to pass into breast milk. Because of the potential for severe side effects in a nursing infant, healthcare providers generally advise against breastfeeding while taking this medication. Potential risks to the baby include:

• Extreme sleepiness or difficulty waking up
• Trouble nursing or poor feeding
• Limpness or low muscle tone
• Slowed or difficult breathing

If a nursing infant shows any signs of unusual sedation or respiratory distress, immediate medical attention is necessary.

Available Forms

Tapentadol is primarily administered by mouth and is available in the following forms:

• Immediate-release oral tablets: These are used for the management of acute pain severe enough to require an opioid analgesic.
• Extended-release oral tablets: These are designed to release the medication slowly over a longer period and are used for chronic pain, including neuropathic pain associated with diabetic peripheral neuropathy, when continuous around-the-clock treatment is necessary.
• Oral solution: This liquid form provides an alternative to tablets for immediate-release dosing.

FDA Approval and Indications

Tapentadol was first approved by the U.S. Food and Drug Administration (FDA) in 2008. It is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The extended-release formulation is specifically approved for chronic pain and neuropathic pain associated with diabetic peripheral neuropathy.

Boxed Warning

The FDA requires a Boxed Warning for tapentadol due to several serious risks:

• Addiction, Abuse, and Misuse: Use of tapentadol can lead to opioid use disorder, which can result in overdose and death.
• Respiratory Depression: Serious, life-threatening, or fatal breathing problems may occur, particularly during treatment initiation or following a dose increase.
• Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can be fatal.
• Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in life-threatening withdrawal symptoms in the newborn.
• Interactions with Benzodiazepines: Using tapentadol with benzodiazepines or other central nervous system depressants may result in profound sedation, respiratory depression, coma, and death.

Regulatory Classification and REMS

Tapentadol is classified as a Schedule II controlled substance under the Controlled Substances Act. Because of the risks associated with opioid medications, tapentadol is part of the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) program. This program requires drug companies to make training available to healthcare providers to ensure the medication is prescribed and used safely.

Understanding Tapentadol Withdrawal

Tapentadol is an opioid medication that can cause physical dependence, meaning the body becomes accustomed to the presence of the drug. If the medication is stopped abruptly or the dose is significantly reduced, the body may experience withdrawal symptoms.

Common Withdrawal Symptoms

Withdrawal symptoms can vary in intensity depending on how long the medication was used and the dosage. Common symptoms include:

• Anxiety and restlessness
• Difficulty falling or staying asleep (insomnia)
• Sweating and shivering
• Nausea, vomiting, or diarrhea
• Muscle aches and stomach cramps
• Tremors or shakiness
• Increased heart rate

Other Possible Symptoms

In some cases, individuals may experience less common withdrawal effects, such as:

• Hallucinations
• Piloerection (goosebumps or hair standing on end)
• Upper respiratory symptoms, such as a runny nose or sneezing
• Irritability

Managing Discontinuation

To prevent or minimize withdrawal symptoms, tapentadol should not be stopped suddenly. Healthcare providers typically recommend a gradual tapering schedule, which involves slowly decreasing the dose over a period of time. If you experience severe withdrawal symptoms while tapering, you should contact your doctor for further guidance.